GI bleeding: problems that persist

Gastrointestinal Endoscopy

Volumn 70, Issue 2, 2009, Pages 225-228

  McCarthy, Denis M ^a  

^a VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; CLOPIDOGREL; ERYTHROMYCIN; ESOMEPRAZOLE; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN UPTAKE INHIBITOR; PROTON PUMP INHIBITOR; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; WARFARIN;

AGE DISTRIBUTION; CLIP; COMORBIDITY; CRYOTHERAPY; DOPPLER ECHOGRAPHY; EDITORIAL; ENDOSCOPIC THERAPY; GASTRIC ULCER BLEEDING; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HEMOSTASIS; HUMAN; LOW DRUG DOSE; MORTALITY; PATIENT COMPLIANCE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; SURGICAL STAPLING; SUTURING METHOD; THROMBOCYTE ANOMALY; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT;

GASTROINTESTINAL HEMORRHAGE; HUMANS;

EID: 67650989383     PISSN: 00165107     EISSN: 10976779     Source Type: Journal    
DOI: 10.1016/j.gie.2008.12.247     Document Type: Editorial

References (35)

1. Loperfido S., Baldo V., Piovesana E., et al. Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest Endosc 70 (2009) 212-224
2. Gralnek I.M., Barkun A.N., and Bardou M. Management of acute bleeding from a peptic ulcer. N Engl J Med 359 (2008) 928-937
3. Standards of Practice Committee. ASGE Guideline: the role of endoscopy in the management of variceal hemorrhage. Gastrointest Endosc 62 (2005) 651-655
4. ASGE Standards of Practice Committee. ASGE guideline: role of endoscopy in acute nonvariceal upper-GI hemorrhage. Gastrointest Endosc 60 (2004) 497-503
5. Bardou M., Toubouti Y., Benhaberou-Brun D., et al. Meta-analysis: proton pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 21 (2005) 677-686
6. Leontiadis G.I., Sharma V.K., and Howden C.W. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 1 (2006) CD002094
7. McCarthy D.M. Management of bleeding peptic ulcer: current status of intravenous proton pump inhibitors. Best Pract Res Clin Gastroenterol 18 Suppl 1 (2004) 7-12
8. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II. Randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21 (2003) 60-65
9. Sonnenberg A. Time trends of ulcer mortality in Europe. Gastroenterology 132 (2007) 2320-2327
10. Sonnenberg A. Time trends of ulcer mortality in non-European countries. Am J Gastroenterol 102 (2007) 1101-1107
11. Rupnow M.F.T., Shacter R.D., Owens D.K., et al. A dynamic transmission model for predicting trends in Helicobacter pylori and associated diseases in the United States. Emerging Infect Dis 6 (2000) 228-237
12. Lanas A., Sekar M.C., and Hirschowitz B.I. Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding/perforation. Gastroenterology 103 (1992) 8629-8637
13. Stack W.A., Atherton J.C., Hawkey G.M., et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 16 (2002) 497-506
14. Pritchard J.P., Kitchingman G.K., Walt R.P., et al. Human gastric mucosal bleeding induced by low-dose aspirin but not by warfarin. Br Med J 298 (1989) 493-496
15. McCarthy D.M. The comparative toxicity of non-steroidal anti-inflammatory drugs. Am J Med 107 (1999) 37-47
16. Rahme E., Nedjar H., Bizzi A., et al. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study. Aliment Pharmacol Ther 26 (2007) 1387-1398
17. Gladding P.A., Webster M.W.I., Farrell H.B., et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. Am J Cardiol 101 (2008) 1060-1063
18. Cryer B., and Feldman M. Effects of very low dose daily, long term aspiring therapy on gastric, duodenal and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117 (1999) 17-25
19. McCarthy D.M. Non-steroidal anti-inflammatory drugs-the clinical dilemmas. Scand J Gastroenterol 192 (1992) 9-16
20. Kurata J., and Abbey D.E. The effect of chronic aspirin use on duodenal and gastric ulcer hospitalization. J Clin Gastroenterol 12 (1990) 260-266
21. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
22. McCarthy D.M. Ulcers, Helicobacter pylori infection, platelets and gastrointestinal complications of non-steroidal anti-inflammatory drugs: what are the connections?. Eur J Surg 587 (2002) 89-99
23. Huang J.-Q., Sridhar S., and Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 359 (2002) 14-22
24. Laine L., Connors L.G., Reicin A., et al. Serious lower gastrointestinal adverse clinical events with non-selective NSAID or coxib use. Gastroenterology 124 (2003) 288-292
25. FDA raising approval bar for NSAID/PPI combos: end-points under review. The Pink Sheet 70 (2008) 31-32
26. Barrett N.E., Holbrook L., Jones S., et al. Future innovations in anti-platelet therapies. Br J Pharmacol 154 (2008) 918-939
27. Fork F.T., Lafolie P., Toth E., et al. Gastro-duodenal tolerance of 75 mg clopidogrel versus 325 mg of aspiring in healthy volunteers. Scand J Gastroenterol 35 (2000) 464-469
28. Bhatt D.I., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of anti-platelet therapy and NSAID use. Am J Gastroenterol 103 (2008) 2890-2897
29. Chan F.K.L., Ching J.Y.L., Hung L.C.T., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
30. Lai K.-C., Chu K.-M., Hui W.-M., et al. Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 4 (2006) 860-865
31. Aubert R.E., Epstein R.S., Teagarden J.R., et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. [abstract]. Circulation 118 S815 (2008) 3998
32. Juurlink D.N., Gomes T., Ko D.T., et al. Population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ (2009 Jan 28) [Epub ahead of print]
33. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Available at: http://www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm. Accessed January 27, 2009.
34. Wessinger S., Kaplan M., Choi L., et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal hemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 23 (2006) 937-944
35. De Abajo F.J., and Garcia-Rodriguez L.A. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy. Arch Gen Psychiatry 65 (2008) 795-803